phase 1_2_completion
saveAbbVie Inc — blinatumomab (Phase I/II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 2 completionSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)Apr 25, 2026 · 165d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalOct 21, 2025 · 351d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalApr 29, 2025 · 526d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalDec 17, 2024 · 659d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 14, 2024 · 845d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalFeb 8, 2024 · 972d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1205d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1205d ago
same company · ±60 days · 6
- phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026
- earningsAbbVie Inc. earningsApr 29, 2026
- grantUNIV OF NORTH CAROLINA CHAPEL HILL — A Trial of Upadacitinib for Non-responsive Eosinophilic esophagitis (ATUNE)Apr 6, 2026
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMar 31, 2026
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 31, 2026
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 31, 2026
comments(0)
5-min edit window · permanent after that